Entia Biosciences, Inc. (OTCQB: ERGO), an authority on the clinical effects of oxidative stress and free radical reactions, today announced a partnership agreement with Tan Republic Franchise Company. This important milestone and strategic partnership follows the release of independent studies on the cellular protection benefits of the potent antioxidant Ergothioneine. The GROH® Ergo Boost product line, positioned for the professional salon and spa industry, is rich in both Vitamin D and is an all-natural source of Ergothioneine.
The $5 billion+ market of Tanning and Light Therapy in the US includes more than 22,632 operators in the industry, in addition to health clubs, spas and beauty salons that also provide tanning as an added service. Concerns about the health risks associated with UV tanning are resulting in increased consumer concern. Cell protection is an important topic in this industry and Tan Republic and many others in this market are looking to provide customers with the latest in technology and innovation to improve the safety and protection of their guests.
"Our GROH® product line provides targeted delivery of key micronutrients directly to cells responsible for healthy skin," said Julia Perederiy Ph.D., Research and Development Scientist at Entia Biosciences.
Entia Biosciences will continue to explore this secondary market and continue to expand its products with the all-natural source of Ergothioneine with the benefits of targeted nutrition and cellular protection. The approach to cellular protection is reinforced in a published study "The Unusual Amino Acid L-Ergothioneine is a Physiologic Cytoprotectant" (1). Study authors stated, "Ergothioneine absorbs UV radiation and prevents DNA breaks and mutations. Ergothioneine may stimulate certain enzymes involved in antioxidant response and repair mechanisms and also have a role in cell proliferation. In addition, Ergothioneine protects against a variety of other ROS and reactive nitrogen species providing cytoprotection at multiple levels."
"We are excited to offer our customers cutting-edge products like those produced by GROH®," said Ariel Peterson of Tan Republic. "The cellular protection offered by GROH® products makes it an ideal addition to our business, while its ability to repair damaged cells ensures that we're offering customers the highest level of innovation available in the market."
(1) Paul & Snyder, "The Unusual Amino Acid L-Ergothioneine Is a Physiologic Cytoprotectant." (Cell Death and Differentiation (2009), 1-7;www.nature.com/cdd)
About Tan Republic
Tan Republic is the largest chain of its type in Oregon and Washington, with nearly 60 salon locations serving over 50,000 guests per month. Tan Republic is proud to provide both UV and sunless tanning options, along with non-invasive spa services, in an upscale, relaxed atmosphere.
Backed by scientific innovation and medical research, all GROH® products and services contain the potent master antioxidant L-Ergothioneine, naturally amplified Vitamin D2, and other important micronutrients and co-factors found in plants and whole foods. These nutrients are unlocked, enhanced, and formulated into Ergo Boost Complex, which works with the body's biological systems to fulfill the everyday nutritional needs that our modern lifestyles fail to provide. With regular use, the GROH® Ergo Boost product line has been shown to promote thicker, fuller hair and lashes, healthier skin, and increased nail strength and growth. For more information on the science behind this revolutionary new approach to health and beauty, please visit www.myGROH.com.
About Entia Biosciences, Inc.
Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2013 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For further information:
SOURCE: Entia BioSciences